SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: A.J. Mullen who wrote (119)	11/19/1997 1:04:00 PM
From: scaram(o)uche	Read Replies (2) of 579

A.J.: No. The cholinesterase projects (there are several) are only related to SIBI's approach, in that both approaches should increase levels of acetylcholine. It's a competitive project, sorta. The cholinesterase approach is proven. It could be additive rather than competitive to to SIB-1553A, which is not a proven approach. Nope, don't know what sort of cash is involved in the Lilly license. An old option from an ex-partner. I therefore think that it's minimal $$$. But it's also another company that has recognized the strength of the patent. This is good. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next